- |||||||||| [VIRTUAL] A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2423;
P2 Funding: Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT04154189.
- |||||||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, doxorubicin hydrochloride / Generic mfg.
[VIRTUAL] The promising role of the extracellular matrix in the activity of trabectedin in soft tissue sarcoma: A prospective study on a UPS and L-sarcoma patient-derived primary culture case series using 3D and zebrafish models (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2416; Second-line therapy may include trabectedin, eribulin, ifosfamide, gemcitabine and dacarbazine with no optimized standard sequential therapy...Combining our STS translational model based on 3D patient-derived primary cultures system and zebrafish we performed genomic-, pharmacological (testing ifosfamide, epirubicin, ifosfamide and epirubicin, doxorubicin, trabectedin, eribulin, dacarbazine and lenvatinib) proteomic- and in silico analysis...Legal entity responsible for the study: Toni Ibrahim. Funding: Has not received any funding.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), everolimus / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC) (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_980; P1b/2, P3 Funding: Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT02501096.
- |||||||||| [VIRTUAL] Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_971;
P1b/2 PEMBRO + axitinib is approved as first-line therapy for advanced RCC...Results For the 104 pts enrolled, median duration of follow-up for OS was 12.3 months, 65% of pts had prior anti-PD-1/PD-L1 and anti-VEGF therapy in combination or sequentially, and 37% of pts had prior nivolumab + ipilimumab...Funding: Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT02501096.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib for thymic carcinomas. (Pubmed Central) - Jul 21, 2020 Clinical trial identification: NCT03951597. No abstract available
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial primary completion date, Metastases: LTHAIC: HAIC Plus Lenvatinib and Toripalimab for Advanced HCC (clinicaltrials.gov) - Jul 13, 2020 P2, N=35, Active, not recruiting, Suspended --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2020 --> Sep 2020
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Combination therapy, Metastases: A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease (clinicaltrials.gov) - Jul 13, 2020 P2, N=41, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2020 --> Sep 2020 N=31 --> 41 | Trial completion date: Mar 2020 --> Feb 2021
|